Improved speed and stability of st-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute st-segment elevation myocardial infarction
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarctionThe Lancet, 2001
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Trial of Abciximab With and Without Low-Dose Reteplase for Acute Myocardial InfarctionCirculation, 2000
- ST-Segment Recovery Adds to the Assessment of TIMI 2 and 3 Flow in Predicting Infarct Wall Motion After Thrombolytic TherapyCirculation, 2000
- Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial InfarctionCirculation, 2000
- Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trialAmerican Heart Journal, 1999
- Abciximab Facilitates the Rate and Extent of ThrombolysisCirculation, 1999
- Toward a New Frontier in Myocardial Reperfusion TherapyCirculation, 1998
- Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarctionThe American Journal of Cardiology, 1994
- Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion.Circulation, 1993